Table 2.

Summary of Ongoing Clinical Trials

Principal Investigator	NCT	Disease	Design	Definition	Target Accrual	Intervention	Outcome
Dirix, P.	NCT03486431	Mixed	Prospective, Phase 1	≤3 lesions	99	SABR	Primary: DLT Secondary: Median PFS Local Control Rate
Bourgier, C.	NCT02089100	Breast	Randomized, Phase 3, Multi-Center	≤5 lesions	280	SABR vs best supportive care	PFS
De Rose, F. Comito, T.	NCT02581670	Breast *Lung/Liver Metastases	Non-Randomized Phase II	1–4 Lesions	40	SBRT	Primary: Local Control, Toxicity Secondary: PFS, OS
Chmura, S.	NCT02364557	Breast	Randomized Phase II/III	1–4 Lesions	402	Systemic Therapy +/− SBRT	Primary: PFS, OS Secondary: Presence of CTC (baseline, after treatment); levels of ctDNA; incidence AE’s; appearance of new metastases
Khoo, V.	NCT02759783	Breast, Prostate, NSCLC	Randomized Phase II/III	≤3 Lesions	245	Standard of Care +/− SBRT	Primary: PFS Secondary: OS, Local Control, Toxicity